News und Analysen
Aurinia Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today
ALPHA MOS : Sweet Ventures invests in BOYDSense
PRESS RELEASE
Sweet Ventures invests in BOYDSense to bring non-invasive glucose monitoring using breath analysis to people with diabetes
Toulouse (France) and Vienna (Austria), October 2nd
Novus Therapeutics Announces One-for-Eighteen Reverse Stock Split
Novus Therapeutics, Inc. (NASDAQ : NVUS) today announced that it has filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to effect a reverse stock split of its
Xencor Presents Initial Data From the Phase 1 Study of Tidutamab in Neuroendocrine Tumors at NANETS’ Multidisciplinary NET Medical Virtual Symposium
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced initial data
Novocure to Report Third Quarter 2020 Financial Results
Novocure (NASDAQ: NVCR) announced today that it will report financial results for the third quarter 2020 on Thursday, October 29, 2020, before the U.S. financial markets open. Novocure’s management
Quidel Announces Preliminary Revenue for Third Quarter 2020
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it expects
Dexcom Schedules Third Quarter 2020 Earnings Release and Conference Call for October 27, 2020 at 4:30 p.m. Eastern Time.
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its third quarter 2020 financial results after market close on Tuesday, October 27, 2020. Management will hold a conference call
Dexcom Schedules Third Quarter 2020 Earnings Release and Conference Call for October 27, 2020 at 4:30 p.m. Eastern Time.
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its third quarter 2020 financial results after market close on Tuesday, October 27, 2020. Management will hold a conference call
Humana Rolls Out 2021 Medicare Advantage Health Plans with Expanded $0 Premiums and Enhanced Benefits in More Counties Nationwide
Humana Inc. (NYSE: HUM) today announced details of its 2021 Medicare product offerings, including Medicare Advantage and Prescription Drug Plans that are built with the benefits and options people
Pfizer Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Investigational Gene Therapy
Pfizer Inc. (NYSE: PFE) today announced that its investigational gene therapy candidate (PF-06939926) being developed to treat Duchenne muscular dystrophy (DMD) received Fast Track designation from
Pfizer Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Investigational Gene Therapy
Pfizer Inc. (NYSE: PFE) today announced that its investigational gene therapy candidate (PF-06939926) being developed to treat Duchenne muscular dystrophy (DMD) received Fast Track designation from
Bayer verschärft Sparprogramm
Pharmagigant Bayer (WKN: BAY001) bestätigte am Mittwochabend seinen angepassten Ausblick für 2020 und legte eine Schätzung für 2021 vor. Der Leverkusener Konzern teilte außerdem eine ganze Menge
Bayer verschärft Sparprogramm
Pharmagigant Bayer (WKN: BAY001) bestätigte am Mittwochabend seinen angepassten Ausblick für 2020 und legte eine Schätzung für 2021 vor. Der Leverkusener Konzern teilte außerdem eine ganze Menge
University of Toledo Medical Center, University of Toledo Physicians Sign Network Agreements with Humana
Leading health and well-being company Humana Inc. (NYSE: HUM) announced today it has signed Medicare and commercial plan network agreements with University of Toledo Medical Center (UTMC) and
Lantheus Holdings Submits New Drug Application to the U.S. FDA for PyL™ (18F-DCFPyL), a PSMA-Targeted Prostate Cancer Imaging Agent
Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture
Acadia Healthcare Announces Pricing of $475 Million Senior Notes Due 2029
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) (the “Company” or “Acadia”) announced today the pricing of its previously announced private offering (the “Offering”) of $475 million in aggregate
Rush Health and Humana Sign Medicare Network Agreement
Clinically-integrated physician and hospital network Rush Health and leading health and well-being company Humana Inc. (NYSE: HUM) today announced an agreement to expand access to quality
Acadia Healthcare Announces Launch of $475 Million Senior Notes Offering
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) (the “Company” or “Acadia”) announced today that it has launched a private offering (the “Offering”) of senior notes due 2029 (the “Notes”), subject
Acadia Healthcare Provides an Update on the U.K. Sale Process
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) (the “Company” or “Acadia”) today provides an update on the sale process for the U.K. business. The Company previously suspended the sale process due
Simulations Plus Extends Partnership with Large Pharmaceutical Company to Further Expand High-Throughput PBPK Capabilities in ADMET Predictor®
Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that
Novocure to Host Virtual Research & Development Day
Novocure (NASDAQ: NVCR) announced today that it will host a virtual Research & Development Day for analysts and investors from 7:30 a.m. to 9:30 a.m. EDT on Thursday, November 12, 2020, to
Quidel Corporation Statement on President Trump’s Announcement of Coronavirus Testing Strategy
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, issued the following statement
U.S. FDA Approves Pfizer’s XELJANZ® (tofacitinib) for the Treatment of Active Polyarticular Course Juvenile Idiopathic Arthritis
Pfizer Inc. (NYSE: PFE) announced today that the United States (U.S.) Food and Drug Administration (FDA) approved XELJANZ® (tofacitinib) for the treatment of children and adolescents 2 years and
U.S. FDA Approves Pfizer’s XELJANZ® (tofacitinib) for the Treatment of Active Polyarticular Course Juvenile Idiopathic Arthritis
Pfizer Inc. (NYSE: PFE) announced today that the United States (U.S.) Food and Drug Administration (FDA) approved XELJANZ® (tofacitinib) for the treatment of children and adolescents 2 years and
LivaNova to Host Conference Call for Third Quarter 2020 Results
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its third quarter 2020 results on Thursday, October 29, 2020 at 12